胰高血糖素样肽1抗动脉粥样硬化作用及其机制的研究进展  

Research Progress of Anti-atherosclerotic Effects and Mechanism of Glucagon Like Peptide-1

作　　者：杨光[1] 李青松[2] 成宪武[1] 

机构地区：[1]延边大学附属医院心内科,吉林省延吉市133000 [2]延边大学附属医院骨科,吉林省延吉市133000

出　　处：《中国全科医学》2017年第8期1009-1014,共6页Chinese General Practice

摘　　要：胰高血糖素样肽1(GLP-1)是一种肠促胰岛素,葡萄糖依赖性分泌胰岛素释放入血,抑制胰高血糖素分泌,显著降低2型糖尿病患者的血糖水平,而且起到维持血糖稳定的作用,减少低血糖发生风险。近年来,GLP-1的非降糖作用备受关注。动物及临床研究已经证实GLP-1除调节血糖和保护胰岛β细胞等生物学功能外,还可以保护血管内皮细胞、调节多种炎性因子及趋化因子,发挥抗炎作用,而且在降低多种心血管危险因素如血糖、血脂、血压、体质量等方面均有积极作用,表明GLP-1在抗动脉粥样硬化作用上具有潜在价值。本文结合基础和临床的最新研究结果,将关于GLP-1抗动脉粥样硬化作用及其机制的研究做一综述。Glucagon- like peptide- 1（ GLP-1） is a kind of incretin,which can promote secretion of insulin into blood（ a releasing process of glucose dependent）,inhibit glucagon secretion,significantly lower blood sugar levels in patients with type 2 diabetes,and play a role in maintaining blood sugar stability and reducing the risk of hypoglycemia. The non-hypoglycemic effect of GLP-1 has received much attention in recent years. Animal and clinical studies have shown that besides the biological functions of regulating blood sugar and protecting pancreatic β cells of GLP-1, it can also protect the vascular endothelium,regulate a variety of inflammatory factors and chemokines,and show the anti- inflammatory effects,moreover,it plays a positive role in reducing multiple cardiovascular risk factors such as blood sugar,blood lipids,blood pressure and body weight. This suggests that GLP-1 has a potential value in the effect of anti- atherosclerosis. Based on the latest theoretical and clinical research results,the paper reviews the studies on the anti- atherosclerosis effects and its mechanism of GLP-1.

关 键 词：胰高血糖素样肽1 动脉粥样硬化 综述 

分 类 号：R543.5[医药卫生—心血管疾病]